Drugs and Medicine

Polymyxin

Question: Between polymyxin and cetrimide antibiotics,which is more effective?How were you able to tell?

Answer: To tell the difference in effectiveness of one antibiotic over another you need to perform an MIC (minimal inhibitory concentration) assay. Grow your organism (bacteria/fungi) in 2-fold serial dilutions of the antibiotics. The lowest concentration that inhibits the growth of your organism is the MIC for that antibiotic. The results will be very different for different organisms, so you need to test each organism individually to determine which compound has the lowest MIC and would therefore be the most effective.

 


Polymyxin Related Products and News

MedPage Today

VA Uses More 'Last-Resort' Antibiotics
MedPage Today
 

Use of 'Last Resort' Antibiotics Still Low, but Rising

Medscape
May 16, 2012 ? Use of the "last resort" antibiotics polymyxin and tigecycline is low but appears to be rising among US Veterans Affairs medical centers (VAMCs), according to a retrospective study published May 16 in PLoS ONE.
 

MedPage Today

Use Of Last-Resort Antibiotics Rises In VA Hospitals, National Study Finds
Pharmaceutical Processing
 

We're Using More of the Few Antibiotics Left

Wired News
The authors find that the use of polymyxin and tigecycline ? the drugs of last resort for the most multi-drug-resistant infections ? rose steadily between 2005 and 2010 at 127 VA centers: 25 percent for polymyxin B and E, and 400 percent for ...
 

Medgadget.com

Five Questions for Dr. Paul Walker of Spectral Diagnostics
Medgadget.com
 

Bacterial Resistance To Drugs Creates Window Of Opportunity For Biopharma Firms

Seeking Alpha
Gram-negative infections are primarily treated using colistin (Coly-Mycin M) marketed by JHP Pharmaceuticals and polymyxin B ((PMB)) marketed by Hycult biotech. Both antibiotics were developed in the 1940s and have potential side effects including ...
 

Resistenzen - Notfall-Antibiotika immer häufiger verordnet

sueddeutsche.de
Doch ist eine steigende Tendenz erkennbar. Diese war vor allem beim Tigecyclin deutlich: Von 2006 bis 2010 hatte sich sein Gebrauch mehr als vervierfacht. Der Anstieg bei Polymyxin fiel etwas schwächer aus. Auffallend war zudem, dass 75 Prozent des ...